At age of 40 weeks, 9 WHHL rabbits were necropsied as a baseline control group for evaluating aortic and coronary atherosclerosis. An additional 18 WHHL rabbits of the same age underwent either a partial ileal bypass (PIB) or a sham operation. Serum cholesterol concentrations were significantly lower in PIB rabbits than in sham-operated rabbits, mean postsurgical values being 7.9 +/- 2.3 mmol/l and 13.2 +/- 2.4 mmol/l, respectively. This effect was mainly due to a lower LDL-cholesterol concentration. Serum triglycerides remained unaffected. Thirty weeks after surgery the PIB and sham rabbits were necropsied and atherosclerosis was evaluated. Progression of atherosclerotic plaque size in the sham group was most prominent in the aortic arch. PIB largely prevented this progression. The frequency of plaque complications in the aortic arch also increased in the sham groups. Here, no significant improvement was found in the PIB group. Extensive examination of the heart showed some affected coronary arteries in every 40-week-old WHHL rabbit. Progression of coronary atherosclerosis during the postsurgical period was small in both sham and PIB groups. However, while PIB did not affect the plaque size, it significantly reduced the number of coronary arteries affected.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/0021-9150(87)90124-9 | DOI Listing |
Int J Mol Sci
October 2024
A.I. Virtanen Institute, University of Eastern Finland, 70210 Kuopio, Finland.
Inflammation is a major component of the pathogenesis of atherosclerosis and the formation of in-stent restenosis (ISR). A novel flavonoid, DHIF, attenuates reactive oxygen species and nf-κB signaling and has potential to limit ISR via antioxidant action. While current drug eluting stents (DESs) perform well in clinical practice, new therapies to prevent ISR without dependance on cytotoxic drugs are warranted.
View Article and Find Full Text PDFInt J Mol Sci
October 2022
Pharmacy Australia Centre of Excellence, School of Pharmacy, University of Queensland, Woolloongabba, QLD 4102, Australia.
Cardiovascular disease is the largest single cause of disease-related mortality worldwide and the major underlying pathology is atherosclerosis. Atherosclerosis develops as a complex process of vascular lipid deposition and retention by modified proteoglycans, endothelial dysfunction and unresolved chronic inflammation. There are a multitude of current therapeutic agents, most based on lowering plasma lipid levels, but, overall, they have a lower than optimum level of efficacy and many deaths continue to arise from cardiovascular disease world-wide.
View Article and Find Full Text PDFActa Radiol
April 2023
Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Background: A study using magnetic resonance imaging (MRI) revealed that ultra-small superparamagnetic iron oxide is phagocytosed by macrophages. However, MRI has limitations in obtaining clear images due to its poor spatial and temporal resolutions.
Purpose: To examine whether the use of dual-energy computed tomography (DECT) facilitated the visualization of carboxymethyl-diethylaminoethyl dextran magnetite ultra-small superparamagnetic iron oxide (CMEADM-U) accumulation in arteriosclerotic lesions using hyperlipidemic rabbits.
Front Endocrinol (Lausanne)
June 2022
Department of Molecular Pathology, Faculty of Medicine, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan.
Background: Intracranial atherosclerosis (ICAS) is one of the most common causes of ischemic stroke, but there are few animal models that can recapitulate its pathological features. In this study, we examined ICAS pathological features and anatomic distributions using three types of hyperlipidemic rabbit models. We also investigated the effect of different lipoprotein profiles and hypertension on ICAS.
View Article and Find Full Text PDFEur J Pharmacol
April 2022
Oniris, NP3, 44300 Nantes, France. Electronic address:
Background And Aim: Metabolic syndrome (MetS) is a global health and economic burden. Finding a suitable pharmacological approach for managing this syndrome is crucial. We explored the therapeutic potential of mirabegron (MIR), a β-adrenergic receptor agonist, as a repurposed agent for the treatment of MetS and its cardiovascular consequences.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!